Treatment of septic shock with immunotherapy.
Sepsis is the thirteenth leading cause of death in the United States. Despite increased knowledge about its pathophysiology, availability of powerful antibiotics, and advanced diagnostic and monitoring techniques, mortality rates have not changed significantly over the past 30 years. Immunotherapy may improve outcome in the critically ill with sepsis, although trial results have been disappointing to date.
Smith
A L
AL
College of Pharmacy, Rutgers University, Piscataway, New Jersey, USA.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000906:Antibodies / Q000276:immunology / Q000627:therapeutic use; D004731:Endotoxins / Q000037:antagonists & inhibitors / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007375:Interleukin-1 / Q000037:antagonists & inhibitors; D010980:Platelet Membrane Glycoproteins / Q000037:antagonists & inhibitors; D016032:Randomized Controlled Trials as Topic; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; D012772:Shock, Septic / Q000276:immunology / Q000382:microbiology / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology
D000276:Adjuvants, Immunologic; D000900:Anti-Bacterial Agents; D000906:Antibodies; D004731:Endotoxins; D007375:Interleukin-1; D010980:Platelet Membrane Glycoproteins; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; D014409:Tumor Necrosis Factor-alpha; C039351:platelet activating factor receptor